1. Academic Validation
  2. Structural basis for receptor selectivity and inverse agonism in S1P5 receptors

Structural basis for receptor selectivity and inverse agonism in S1P5 receptors

  • Nat Commun. 2022 Aug 12;13(1):4736. doi: 10.1038/s41467-022-32447-1.
Elizaveta Lyapina # 1 Egor Marin # 1 2 Anastasiia Gusach # 1 3 Philipp Orekhov 1 4 5 Andrey Gerasimov 6 Aleksandra Luginina 1 Daniil Vakhrameev 1 Margarita Ergasheva 1 Margarita Kovaleva 1 Georgii Khusainov 1 7 Polina Khorn 1 Mikhail Shevtsov 1 Kirill Kovalev 1 8 Sergey Bukhdruker 1 Ivan Okhrimenko 1 Petr Popov 1 9 Hao Hu 10 Uwe Weierstall 10 Wei Liu 11 Yunje Cho 12 Ivan Gushchin 1 Andrey Rogachev 1 13 Gleb Bourenkov 8 Sehan Park 14 Gisu Park 14 Hyo Jung Hyun 14 Jaehyun Park 14 15 Valentin Gordeliy 16 Valentin Borshchevskiy 17 18 Alexey Mishin 19 Vadim Cherezov 20
Affiliations

Affiliations

  • 1 Research Сenter for Molecular Mechanisms of Aging and Age-related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny, 141701, Russia.
  • 2 Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands.
  • 3 MRC Laboratory of Molecular Biology, Cambridge, CB2 0QH, UK.
  • 4 Faculty of Biology, Lomonosov Moscow State University, Moscow, 119991, Russia.
  • 5 Faculty of Biology, Shenzhen MSU-BIT University, Shenzhen, 518172, China.
  • 6 Vyatka State University, Kirov, 610020, Russia.
  • 7 Division of Biology and Chemistry, Paul Scherrer Institute, Forschungsstrasse 111, 5232, Villigen, PSI, Switzerland.
  • 8 European Molecular Biology Laboratory, Hamburg unit c/o DESY, Hamburg, Germany.
  • 9 iMolecule, Skolkovo Institute of Science and Technology, Bolshoy Boulevard 30, bld. 1, Moscow, 121205, Russia.
  • 10 Department of Physics, Arizona State University, Tempe, AZ, 85281, USA.
  • 11 Cancer Center and Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
  • 12 Department of Life Science, Pohang University of Science and Technology, Pohang, Republic of Korea.
  • 13 Joint Institute for Nuclear Research, Dubna, 141980, Russia.
  • 14 Pohang Accelerator Laboratory, POSTECH, Pohang, 37673, Republic of Korea.
  • 15 Department of Chemical Engineering, POSTECH, Pohang, 37673, Republic of Korea.
  • 16 Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CEA, CNRS, Grenoble, 38400, France.
  • 17 Research Сenter for Molecular Mechanisms of Aging and Age-related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny, 141701, Russia. [email protected].
  • 18 Joint Institute for Nuclear Research, Dubna, 141980, Russia. [email protected].
  • 19 Research Сenter for Molecular Mechanisms of Aging and Age-related Diseases, Moscow Institute of Physics and Technology, Dolgoprudny, 141701, Russia. [email protected].
  • 20 Bridge Institute, Department of Chemistry, University of Southern California, Los Angeles, CA, 90089, USA. [email protected].
  • # Contributed equally.
Abstract

The bioactive lysophospholipid sphingosine-1-phosphate (S1P) acts via five different subtypes of S1P receptors (S1PRs) - S1P1-5. S1P5 is predominantly expressed in nervous and immune systems, regulating the egress of natural killer cells from lymph nodes and playing a role in immune and neurodegenerative disorders, as well as carcinogenesis. Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor subtype selectivity, which leads to side effects. In this article, we describe a 2.2 Å resolution room temperature crystal structure of the human S1P5 receptor in complex with a selective inverse agonist determined by serial femtosecond crystallography (SFX) at the Pohang Accelerator Laboratory X-Ray Free Electron Laser (PAL-XFEL) and analyze its structure-activity relationship data. The structure demonstrates a unique ligand-binding mode, involving an allosteric sub-pocket, which clarifies the receptor subtype selectivity and provides a template for structure-based drug design. Together with previously published S1PR structures in complex with antagonists and agonists, our structure with S1P5-inverse agonist sheds light on the activation mechanism and reveals structural determinants of the inverse agonism in the S1PR family.

Figures